Vectus Biosystems Ltd
ASX:VBS
Prices of ASX stocks are not being updated. The latest VBS price on Alpha Spread is from Oct 14, 2026. Financials, forecasts and intrinsic value keep updating.
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Intrinsic Value
The intrinsic value of Vectus Biosystems Ltd (VBS) under the Base Case is 0.016 AUD per share. Compared with the last price of 0.105 AUD on Oct 14, the stock appears Overvalued by 84% .
The intrinsic value is calculated using valuation multiples.
Do our valuations actually work? See backtest results .
Fundamental Analysis
What Vectus Biosystems Does
Vectus Biosystems Ltd. is a drug discovery and development company, which engages in the treatment for fibrosis and high blood pressure, which includes therapeutics for diseases in the fibrotic market namely heart, kidney, and liver disease. The company is headquartered in Rosebery, New South Wales. The company went IPO on 2016-02-23. The firm focuses on medical research and development. The company is engaged in developing a treatment for fibrosis and high blood pressure, which includes the treatment for diseases in the fibrotic market, namely heart, kidney, and liver diseases.
- Headquarters
- Australia AU
- IPO date
- Feb 23, 2016
Continue VBS Research
Decided on Vectus Biosystems? Get an email when VBS reaches the price you’d buy at. Free with an account.
What is the Intrinsic Value of one VBS stock?
The intrinsic value for Vectus Biosystems Ltd (VBS) under the Base Case is 0.016 AUD.
Is VBS stock undervalued or overvalued?
Compared with the last price of 0.105 AUD on Oct 14, the stock appears Overvalued by 84% .